JP4778449B2 - Pde4インヒビターとしての2−(ピペリジン−4−イル)−4,5−ジヒドロ−2h−ピリダジン−3−オン誘導体 - Google Patents

Pde4インヒビターとしての2−(ピペリジン−4−イル)−4,5−ジヒドロ−2h−ピリダジン−3−オン誘導体 Download PDF

Info

Publication number
JP4778449B2
JP4778449B2 JP2006551846A JP2006551846A JP4778449B2 JP 4778449 B2 JP4778449 B2 JP 4778449B2 JP 2006551846 A JP2006551846 A JP 2006551846A JP 2006551846 A JP2006551846 A JP 2006551846A JP 4778449 B2 JP4778449 B2 JP 4778449B2
Authority
JP
Japan
Prior art keywords
ring
alkyl
methyl
phenyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006551846A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007520528A5 (cg-RX-API-DMAC7.html
JP2007520528A (ja
Inventor
ハッツェルマン アルミン
バルズィヒ ヨハネス
マルクス デーゲンハルト
クライ ハンス−ペーター
アー エム クリスティアンス ヨハネス
エム ペー ベー メンゲ ヴィロ
ヤン ステルク ヘールト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Nycomed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed GmbH filed Critical Nycomed GmbH
Publication of JP2007520528A publication Critical patent/JP2007520528A/ja
Publication of JP2007520528A5 publication Critical patent/JP2007520528A5/ja
Application granted granted Critical
Publication of JP4778449B2 publication Critical patent/JP4778449B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
JP2006551846A 2004-02-04 2005-02-01 Pde4インヒビターとしての2−(ピペリジン−4−イル)−4,5−ジヒドロ−2h−ピリダジン−3−オン誘導体 Expired - Fee Related JP4778449B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04002420.0 2004-02-04
EP04002420 2004-02-04
PCT/EP2005/050415 WO2005075456A1 (en) 2004-02-04 2005-02-01 2-(piperidin-4-yl) -4, 5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors

Publications (3)

Publication Number Publication Date
JP2007520528A JP2007520528A (ja) 2007-07-26
JP2007520528A5 JP2007520528A5 (cg-RX-API-DMAC7.html) 2008-03-21
JP4778449B2 true JP4778449B2 (ja) 2011-09-21

Family

ID=34833569

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006551846A Expired - Fee Related JP4778449B2 (ja) 2004-02-04 2005-02-01 Pde4インヒビターとしての2−(ピペリジン−4−イル)−4,5−ジヒドロ−2h−ピリダジン−3−オン誘導体

Country Status (9)

Country Link
US (2) US7494990B2 (cg-RX-API-DMAC7.html)
EP (1) EP1716133B1 (cg-RX-API-DMAC7.html)
JP (1) JP4778449B2 (cg-RX-API-DMAC7.html)
AT (1) ATE390419T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005210042B2 (cg-RX-API-DMAC7.html)
CA (1) CA2554797C (cg-RX-API-DMAC7.html)
DE (1) DE602005005638T2 (cg-RX-API-DMAC7.html)
ES (1) ES2304692T3 (cg-RX-API-DMAC7.html)
WO (1) WO2005075456A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101657441B (zh) * 2007-05-16 2013-09-11 塔科达有限责任公司 作为pde4抑制剂的吡唑啉酮衍生物
AU2013234404B2 (en) * 2007-05-16 2016-04-28 Takeda Gmbh Pyrazolone Derivatives as PDE4 Inhibitors
AR074318A1 (es) * 2008-11-14 2011-01-05 Nycomed Gmbh Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias.
MX2013014888A (es) 2011-06-17 2014-02-27 Takeda Gmbh Novedosos derivados de ftalazinona-pirrolopirimidinacarboxamida.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB858792A (en) * 1958-02-10 1961-01-18 Sandoz Ltd New pyridazine derivatives and processes for their manufacture
JPH08291145A (ja) * 1995-04-20 1996-11-05 Merck Patent Gmbh アリールアルキルピリダジノン化合物
WO2002064584A1 (en) * 2001-02-15 2002-08-22 Altana Pharma Ag Phthalayinone-piperidino-derivatives as pde4 inhibitors
WO2002085906A2 (en) * 2001-04-25 2002-10-31 Altana Pharma Ag Phthalazinones derivatives useful as pde4/7 inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5267027A (en) 1991-04-30 1993-11-30 Sanyo Electric Co., Ltd. Comb filter-type Y/C separator circuit
JP3245165B2 (ja) 1991-10-09 2002-01-07 シンテックス(ユー・エス・エイ)・インコーポレイテッド ピリドピリダジノンおよびピリダジンチオン化合物
DE4134893A1 (de) 1991-10-23 1993-04-29 Merck Patent Gmbh Thiadiazinone
DE4310699A1 (de) 1993-04-01 1994-10-06 Merck Patent Gmbh Thiadiazinone
US5798349A (en) 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
DE19502699A1 (de) 1995-01-28 1996-08-01 Merck Patent Gmbh Arylalkyl-thiadiazinone
DE19533975A1 (de) 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
DE19604388A1 (de) 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone
SK283270B6 (sk) 1997-01-15 2003-04-01 Altana Pharma Ag Ftalazinóny, farmaceutické prostriedky s ich obsahom a ich použitie
US6380196B1 (en) 1997-12-15 2002-04-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Dihydrobenzofurans
AU1760399A (en) 1997-12-15 1999-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh New phthalazinones
SI1070056T1 (en) * 1998-03-14 2004-12-31 Altana Pharma Ag Phthalazinone pde iii/iv inhibitors
WO2001019818A1 (en) 1999-09-14 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone derivatives as pd3/4 inhibitors
ATE374189T1 (de) 1999-10-25 2007-10-15 Nycomed Gmbh Phthalazinon-derivate als pde 4 hemmer
AU781137B2 (en) 1999-10-25 2005-05-05 Altana Pharma Ag Tetrahydrothiopy ranphthalazinone derivatives as PDE4 inhibitors
CN1471515A (zh) 2000-06-05 2004-01-28 ��̹��ҽҩ��˾ 作为β2-肾上腺素受体激动剂及PDE-4抑制剂的有效的化合物
BR0209076A (pt) 2001-04-25 2004-08-10 Altana Pharma Ag Derivados de piperazino e seu uso como inibidor de pde4
DE10150517A1 (de) 2001-10-12 2003-04-17 Merck Patent Gmbh Verwendung von Phosphodiesterase IV-Inhibitoren
US20060166995A1 (en) 2002-08-10 2006-07-27 Altana Pharma Ag Piperidine-n-oxide-derivatives
US20060167001A1 (en) 2002-08-10 2006-07-27 Sterk Jan G Pyridazinone-derivatives as pde4 inhibitors
WO2004018449A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
HRP20050198A2 (hr) 2002-08-10 2006-04-30 Altana Pharma Ag Piperidin-piridazoni i ftalazoni kao inhibitori pde4
AU2003214725A1 (en) 2002-08-20 2004-03-11 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
US20080227790A1 (en) 2004-02-04 2008-09-18 Altana Pharma Ag Pyridazinone Derivatives and their Use as Pde4 Inhibitors
EP1720854A1 (en) 2004-02-04 2006-11-15 Altana Pharma AG Phthalzinone derivatives as pde4 inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB858792A (en) * 1958-02-10 1961-01-18 Sandoz Ltd New pyridazine derivatives and processes for their manufacture
JPH08291145A (ja) * 1995-04-20 1996-11-05 Merck Patent Gmbh アリールアルキルピリダジノン化合物
WO2002064584A1 (en) * 2001-02-15 2002-08-22 Altana Pharma Ag Phthalayinone-piperidino-derivatives as pde4 inhibitors
WO2002085906A2 (en) * 2001-04-25 2002-10-31 Altana Pharma Ag Phthalazinones derivatives useful as pde4/7 inhibitors

Also Published As

Publication number Publication date
DE602005005638T2 (de) 2009-05-14
AU2005210042A1 (en) 2005-08-18
CA2554797C (en) 2012-09-04
WO2005075456A1 (en) 2005-08-18
WO2005075456A8 (en) 2006-03-02
AU2005210042B2 (en) 2011-04-21
US20090131448A1 (en) 2009-05-21
CA2554797A1 (en) 2005-08-18
ATE390419T1 (de) 2008-04-15
US7820669B2 (en) 2010-10-26
DE602005005638D1 (de) 2008-05-08
EP1716133B1 (en) 2008-03-26
US7494990B2 (en) 2009-02-24
ES2304692T3 (es) 2008-10-16
EP1716133A1 (en) 2006-11-02
US20070179146A1 (en) 2007-08-02
JP2007520528A (ja) 2007-07-26

Similar Documents

Publication Publication Date Title
JP2005538138A (ja) Pde4インヒビターとしてのピリダジノン誘導体
JP2005538137A (ja) ピペリジン−n−オキシド誘導体
JP2005537312A (ja) 新規のフェナントリジン
US9090597B2 (en) Pyrazolone derivatives as PDE4 inhibitors
US7820669B2 (en) 2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one derivatives as PDE4 inhibitors
JP2007500685A (ja) 新規の6−フェニルフェナントリジン
JP2007500686A (ja) 新規の6−フェニルフェナントリジン
JP2008528556A (ja) 新規の6−ピリジルフェナントリジン
WO2005075457A1 (en) Phthalazinone-derivatives as pde4 inhibitors
US20080227790A1 (en) Pyridazinone Derivatives and their Use as Pde4 Inhibitors
JP2008531654A (ja) 炎症性疾患の治療のためのPDE4インヒビターとしての6−ヘテロアリール−1,2,3,4,4a,10b−ヘキサヒドロフェナントリジン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080129

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110519

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110623

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110701

R150 Certificate of patent or registration of utility model

Ref document number: 4778449

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140708

Year of fee payment: 3

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140708

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees